What ads

The short version: the evidence here cannot separate insulin effects from gastric emptying for tirzepatide during acute illness, because none of the retrieved studies tested that question.

The retrieval surfaced nothing on tirzepatide, GLP-1/GIP drugs, or acute infection. What it did find is indirect. One study shows that severe gut injury in critically ill adults comes with delayed gastric emptying, high residual volumes, and worse outcomes [1]. That tells you acute illness itself can slow the stomach, but it does not tell you how tirzepatide interacts with that.

The gastric emptying literature is all surgical or functional dyspepsia. Delayed emptying is linked to nausea, vomiting, and fullness [3], and female sex roughly doubles the odds [2]. Those are the symptoms you would expect to worsen if you keep injecting a drug that already slows emptying while your gut is inflamed.

The insulin side is even thinner here. Nothing in the retrieval measures insulin sensitivity during acute illness or under tirzepatide. The prior clamp data you discussed is not in this evidence block, so I cannot cite it. What the records do show is that stopping enteral nutrition in sick patients triples the odds of severe gut injury [1], which is a warning about withholding food, not about pausing a drug.

The honest answer: the mechanism split you are asking about is unstudied in this exact setting. Acute illness slows gastric emptying on its own [1]. Tirzepatide slows it further as a known drug effect, though that specific claim is outside these records. The insulin question is a blank.

My call: the evidence is not clear on whether insulin or gastric emptying dominates here, and no retrieved study supports continuing or pausing tirzepatide during acute illness. Confidence: low, because the retrieval simply does not reach this question.